RxDoctor Payments Data

Samantha Kramer

Physician Assistant · Cedar Bluff, VANPI 1144902636

Payments from drug & device makers

$2,755in general payments, 2019–2025

Across 101 payments — averaging $27.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$594
  • Neurocrine Biosciences, Inc.$546
  • Johnson & Johnson$455
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$290
  • E.r. Squibb & Sons, L.L.C.$273
  • AbbVie$170
  • plus $427 from 4 others

What the payments were for

  • Food & beverage$2,63195%
  • Education$1245%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,755 in reported general payments places this provider in the 85th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$7,776
Medicare patients
48
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$94,318
Aripiprazole104$18,656
Paliperidone ErPaliperidone12$4,406
Ziprasidone Hcl19$2,539
Trifluoperazine Hcl12$2,169
Quetiapine Fumarate80$2,038
Lamotrigine ErLamotrigine12$1,304
Risperidone184$1,294
Carbamazepine ErCarbamazepine22$1,266
Hydroxyzine Pamoate85$867
Sertraline Hcl121$791
Trazodone Hcl48$685
Olanzapine27$563
Fluoxetine Hcl45$413
Divalproex Sodium11$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$546$94,31812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Cedar Bluff

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →